Aurobindo Pharma’s Dyrupeg faces Health Canada compliance notice

CuraTeQ Biologics, a part of Aurobindo Pharma, has secured a crucial approval from Health Canada for its biosimilar drug Dyrupeg. This medication helps cancer patients with low neutrophil counts. The approval confirms Dyrupeg's high similarity to an existing reference biologic drug. Earlier, Dyrupeg also gained marketing authorization in the European Union and the UK.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xyQkAH5
via IFTTT